Worth reading
65In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
3102489
Japanese yen (¥9,307,467 per patient)Wording
Conditional
How definitive the wording is.Announced details
Telomelysin Injection (generic name: suratadenoturev; development code: OBP-301)
Applicable field (uses covered by this announcement)
Treatment of esophageal cancer
Launch dateSales scheduled to begin on 21 August 2026; covered under health insurance effective 13 August 2026
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
Sales partner
CounterpartyFUJIFILM Toyama Chemical Co., Ltd.
Offering price
Calculated National Health Insurance price: ¥3,102,489 (¥9,307,467 per patient)
Impact on Business Performance
The impact of this announcement on the company's financial results is currently under review. Product sales revenue is expected to be recorded from the fiscal year ending December 2026.
The company does not address Contract Value.
Source (materials cited by the company)
Official Gazette; Central Social Insurance Medical Council (Chuikyo)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin Injection (generic name: suratadenoturev; development code: OBP-301) |
| Counterparty | FUJIFILM Toyama Chemical Co., Ltd. |
| Relationship with the Company | Sales partner |
| Offering price | Calculated National Health Insurance price: ¥3,102,489 (¥9,307,467 per patient) |
| Launch date | Sales scheduled to begin on 21 August 2026; covered under health insurance effective 13 August 2026 |
| Applicable area | Treatment of esophageal cancer |
| Impact on Business Performance | The impact of this announcement on the company's financial results is currently under review. Product sales revenue is expected to be recorded from the fiscal year ending December 2026. |
| Source | Official Gazette; Central Social Insurance Medical Council (Chuikyo) |
Items this document does not state (10)
Counterparty overviewContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The product was listed on the National Health Insurance Drug Price List pursuant to an Official Gazette notice and will be covered under health insurance effective 13 August 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.